These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

627 related items for PubMed ID: 27671301

  • 1. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
    Wang D, Chang R, Wang G, Hu B, Qiang Y, Chen Z.
    Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
    [Abstract] [Full Text] [Related]

  • 2. Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma.
    Mok WC, Wasser S, Tan T, Lim SG.
    World J Gastroenterol; 2012 Jul 21; 18(27):3527-36. PubMed ID: 22826617
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
    McCarroll JA, Dwarte T, Baigude H, Dang J, Yang L, Erlich RB, Kimpton K, Teo J, Sagnella SM, Akerfeldt MC, Liu J, Phillips PA, Rana TM, Kavallaris M.
    Oncotarget; 2015 May 20; 6(14):12020-34. PubMed ID: 25557168
    [Abstract] [Full Text] [Related]

  • 4. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
    Xu L, Zhu Y, Shao J, Chen M, Yan H, Li G, Zhu Y, Xu Z, Yang B, Luo P, He Q.
    Br J Cancer; 2017 Apr 11; 116(8):1027-1036. PubMed ID: 28267710
    [Abstract] [Full Text] [Related]

  • 5. STK39 is a novel kinase contributing to the progression of hepatocellular carcinoma by the PLK1/ERK signaling pathway.
    Zhang C, Wang X, Fang D, Xu P, Mo X, Hu C, Abdelatty A, Wang M, Xu H, Sun Q, Zhou G, She J, Xia J, Hui KM, Xia H.
    Theranostics; 2021 Apr 11; 11(5):2108-2122. PubMed ID: 33500714
    [Abstract] [Full Text] [Related]

  • 6. Polo-like kinase 1 contributes to the tumorigenicity of BEL-7402 hepatoma cells via regulation of Survivin expression.
    He Z, Wu J, Dang H, Lin H, Zheng H, Zhong D.
    Cancer Lett; 2011 Apr 28; 303(2):92-8. PubMed ID: 21330050
    [Abstract] [Full Text] [Related]

  • 7. Systemic delivery of siRNA with cationic lipid assisted PEG-PLA nanoparticles for cancer therapy.
    Yang XZ, Dou S, Sun TM, Mao CQ, Wang HX, Wang J.
    J Control Release; 2011 Dec 10; 156(2):203-11. PubMed ID: 21839126
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Therapeutic targeting of PLK1 in TERT promoter-mutant hepatocellular carcinoma.
    Tang Q, Hu G, Sang Y, Chen Y, Wei G, Zhu M, Chen M, Li S, Liu R, Peng Z.
    Clin Transl Med; 2024 May 10; 14(5):e1703. PubMed ID: 38769666
    [Abstract] [Full Text] [Related]

  • 11. A biomimetic nanovector-mediated targeted cholesterol-conjugated siRNA delivery for tumor gene therapy.
    Ding Y, Wang W, Feng M, Wang Y, Zhou J, Ding X, Zhou X, Liu C, Wang R, Zhang Q.
    Biomaterials; 2012 Dec 10; 33(34):8893-905. PubMed ID: 22979990
    [Abstract] [Full Text] [Related]

  • 12. Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.
    Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX.
    Cancer Biother Radiopharm; 2011 Aug 10; 26(4):427-36. PubMed ID: 21797676
    [Abstract] [Full Text] [Related]

  • 13. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
    Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF.
    Int J Radiat Oncol Biol Phys; 2010 May 01; 77(1):253-60. PubMed ID: 20394857
    [Abstract] [Full Text] [Related]

  • 14. [Study of growth inhibition of gastric cancer cells by sRNA targeting polo like kinase 1 in vitro and vivo].
    Lan B, Liu BY, Cheng XH, Qu Y, Zhang XQ, Cai Q, Dai QB, Zhu ZG.
    Zhonghua Wai Ke Za Zhi; 2006 Jan 01; 44(1):40-4. PubMed ID: 16620646
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Escheriosome-mediated cytosolic delivery of PLK1-specific siRNA: potential in treatment of liver cancer in BALB/c mice.
    Chauhan A, Zubair S, Nadeem A, Ansari SA, Ansari MY, Mohammad O.
    Nanomedicine (Lond); 2014 Apr 01; 9(4):407-20. PubMed ID: 24910873
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.